Qiagen NV
QGEN
Company Profile
Business description
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
Contact
Hulsterweg 82
VenloLI5912 PL
NLDT: +31 773556600
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
5,700
Stocks News & Analysis
stocks
Ask the analyst: Are markets missing something with CSL?
I catch up with Shane Ponraj after an eventful reporting season for healthcare major CSL.
stocks
This ASX stock’s bubble has well and truly burst
Pandemic related tailwinds are a distant memory for Reece, which looks set to face more competition in Australia.
stocks
Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026
Tesla’s challenges echo past issues the company has overcome, says Zevenbergen’s Joe Dennison.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,231.10 | 2.60 | 0.03% |
| CAC 40 | 7,749.73 | 39.92 | 0.52% |
| DAX 40 | 24,072.74 | 80.13 | -0.33% |
| Dow JONES (US) | 45,449.88 | 31.81 | 0.07% |
| FTSE 100 | 9,249.50 | 16.30 | -0.18% |
| HKSE | 25,201.76 | 323.16 | -1.27% |
| NASDAQ | 21,510.15 | 34.12 | -0.16% |
| Nikkei 225 | 42,520.27 | 125.87 | 0.30% |
| NZX 50 Index | 12,861.84 | 96.14 | -0.74% |
| S&P 500 | 6,462.95 | 2.99 | -0.05% |
| S&P/ASX 200 | 8,960.50 | 0.70 | -0.01% |
| SSE Composite Index | 3,800.35 | 68.03 | -1.76% |